The choice of antibiotic monotherapy or combination therapy to treat Pseudomonas aeruginosa bacteraemia is controversial. The aim of this review was to compare both types of therapy to determine which delivers the best outcome for P. aeruginosa bacteraemia. We systematically searched electronic bibliographic databases, including PubMed, Ovid EMBASE and The Cochrane Library, for clinical studies that compared combination therapy with monotherapy in the treatment of P. aeruginosa bacteraemia. Eligible articles were analysed using Stata(®)/SE software v.12.0. Stratification analysis was conducted by study design and treatment type. Publication bias was assessed using Begg's funnel plot and Egger's test. Ten studies (eight retrospective and two prospective) involving 1239 patients were analysed. We found no difference between combination therapy and monotherapy when the data were combined (odds ratio = 0.89, 95% confidence interval 0.57-1.40; P = 0.614) or when data were analysed in subgroups. Neither combination therapy nor monotherapy treatment appears to have a significant effect on mortality rates in patients with P. aeruginosa bacteraemia. Further studies evaluating the effects of combination therapy or monotherapy in more specialised cases, such as when encountering a multidrug-resistant organism, are necessary.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijantimicag.2013.09.002DOI Listing

Publication Analysis

Top Keywords

aeruginosa bacteraemia
20
combination therapy
20
therapy monotherapy
16
pseudomonas aeruginosa
8
retrospective prospective
8
monotherapy treatment
8
therapy
7
combination
6
monotherapy
6
aeruginosa
5

Similar Publications

Comparative analysis of virulence factors produced by strains isolated from chronic wounds or bloodstream infections.

MicroPubl Biol

December 2024

Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.

is an important pathogen associated with both chronic wounds and bloodstream infections. Virulence factors required for the establishment of acute and chronic infections differ substantially. Since bacteremia can be a severe outcome of wound colonization, we performed a comparative analysis of virulence between strains isolated from the bloodstream and chronic wounds.

View Article and Find Full Text PDF

Introduction: Healthcare-associated infections are an important cause of morbidity and mortality in the pediatric population and a growing problem in intensive care services. However, limited data are available on these infections in the Portuguese pediatric population. This study aimed to estimate its prevalence rate in a Portuguese pediatric intensive care unit, identifying the most frequent microorganisms and their antibiotic resistance profiles.

View Article and Find Full Text PDF

Objectives: To quantify the global and regional burden of bloodstream infections associated with and attributable to carbapenem-resistant Gram-negative bacteria.

Methods: We extracted data from the MICROBE database, which includes the estimated burden of 23 pathogens and 88 pathogen-drug combinations across 12 major infectious syndromes globally in 2019. The number and rate of deaths, as well as disability-adjusted life-years linked to bloodstream infections, were systematically analyzed.

View Article and Find Full Text PDF

Pseudomonas aeruginosa produces a wealth of virulence factors whose production is controlled via an intricate regulatory systems network. Here, we uncover a major player in the evolution and regulation of virulence that enhances host colonization and antibiotic resistance. By characterizing a collection of mutants lacking the stringent response (SR), a system key for virulence, we show that the loss of the central regulator MexT bypasses absence of the SR, restoring full activation of virulence pathways.

View Article and Find Full Text PDF

Background: Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce. Pharmacokinetic and pharmacodynamic differences between the agents might affect clinical response rates. We aimed to compare the effectiveness of ceftolozane-tazobactam and ceftazidime-avibactam for treatment of invasive multidrug-resistant P aeruginosa infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!